Literature DB >> 20093310

StarClose vascular closure device: safety and efficacy of deployment and reaccess in a neurointerventional radiology service.

R A McTaggart1, D Raghavan, R A Haas, M V Jayaraman.   

Abstract

BACKGROUND AND
PURPOSE: Obtaining safe and effective closure of the femoral access site following neurointerventional procedures can sometimes be challenging, especially in patients on anti-coagulation or anti-platelet therapy. The purpose of this study was to evaluate the safety and efficacy of a novel percutaneous closure device that employs a nitinol clip-mediated extravascular closure strategy following neurointerventional procedures.
MATERIALS AND METHODS: We performed a retrospective review of all patients who underwent neurointerventional procedures at our institution between January 1, 2006 and December 31, 2008. We evaluated the safety and efficacy of the StarClose device in patients undergoing first and repeat procedures. Groin complications were classified as self-limited hematoma, hematoma requiring transfusion, other/minor (pseudoaneurysm, infection), and other/major (vascular complication).
RESULTS: StarClose device use was attempted in 281 of 352 cases (79.8%) with success reported in 269 cases (95.7%). Minor and major complications occurred in 0.7% and 0.4% of patients, respectively. There was one major vascular complication. Repeat use was performed in 84 patients with 100% success and a 2.3% minor complication rate. Time to reaccess ranged from 1 to 1036 days (mean, 105 days).
CONCLUSIONS: The StarClose device achieves rapid and safe femoral arterial closure in patients, both for primary closure and after reaccess.

Entities:  

Mesh:

Year:  2010        PMID: 20093310      PMCID: PMC7963929          DOI: 10.3174/ajnr.A2001

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  9 in total

1.  Early mobilization after percutaneous catheterization and vascular closure with a novel device (Star-Close).

Authors:  Alessandro Desideri; Diego Tonello; Sebastian Coscarelli; Ferdinando Alitto; Alessandro Daniotti; Raffaello Chioin
Journal:  Am J Cardiol       Date:  2005-09-27       Impact factor: 2.778

2.  Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition.

Authors:  Peter N Ruygrok; John A Ormiston; James T Stewart; Mark W I Webster; Seif El Jack; Stephanie Simpson-Plaumann; I Patrick Kay; Tony M Chou
Journal:  Catheter Cardiovasc Interv       Date:  2005-10       Impact factor: 2.692

Review 3.  Efficacy and safety of the perclose closer s device after neurointerventional procedures: prospective study and literature review.

Authors:  Kamran Khaghany; Firas Al-Ali; Thomas Spigelmoyer; Ron Pimentel; Kurt Wharton
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

4.  Prospective nonrandomized trial of manual compression and Angio-Seal and Starclose arterial closure devices in common femoral punctures.

Authors:  Lakshmi A Ratnam; Jowad Raja; Graham J Munneke; Robert A Morgan; Anna-Maria Belli
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Mar-Apr       Impact factor: 2.740

5.  StarClose vascular closure device: prospective study on 222 deployments in an interventional radiology practice.

Authors:  Atique Imam; Ranjana M S Carter; Jane Phillips-Hughes; Philip Boardman; Raman Uberoi
Journal:  Cardiovasc Intervent Radiol       Date:  2007-06-22       Impact factor: 2.740

6.  Clinical experience of StarClose vascular closure device in patients with first and recurrent femoral punctures.

Authors:  Edgar Lik-Wui Tay; Melissa Co; Bee-Choo Tai; Yian Ping Lee; Adrian Low; Yean-Teng Lim; Huay-Cheem Tan; Chi-Hang Lee
Journal:  J Interv Cardiol       Date:  2008-02       Impact factor: 2.279

7.  Clinical experience with a circumferential clip-based vascular closure device in diagnostic catheterization.

Authors:  James Hermiller; Charles Simonton; Tom Hinohara; Daniel Lee; Louis Cannon; Michael Mooney; Charles O'Shaughnessy; Harold Carlson; Richard Fortuna; Carol Anne Yarbrough; Michael Zapien; Tony Chou
Journal:  J Invasive Cardiol       Date:  2005-10       Impact factor: 2.022

8.  The StarClose Vascular Closure System: interventional results from the CLIP study.

Authors:  J B Hermiller; C Simonton; T Hinohara; D Lee; L Cannon; M Mooney; C O'Shaughnessy; H Carlson; R Fortuna; M Zapien; D R Fletcher; K DiDonato; T M Chou
Journal:  Catheter Cardiovasc Interv       Date:  2006-11       Impact factor: 2.692

9.  A randomised controlled trial comparing StarClose and AngioSeal vascular closure devices in a district general hospital--the SCOAST study.

Authors:  R A Veasey; J K Large; J Silberbauer; G Paul; W Taggu; S Ellery; V S Rathore; G W Lloyd; N R Patel; A N Sulke
Journal:  Int J Clin Pract       Date:  2008-06       Impact factor: 2.503

  9 in total
  5 in total

1.  Safety and feasibility of a novel vascular closure device in neurointerventional procedures.

Authors:  Ammar Taha; Ellen K Walsh; Kathryn A Wright; Iftikhar Ahmed; Nucharin Supakul; Eric E Awwad; Juan G Tejada
Journal:  Interv Neuroradiol       Date:  2013-09-26       Impact factor: 1.610

2.  The cost of closure.

Authors:  H J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

3.  Prospective comparison of angio-seal versus manual compression for hemostasis after neurointerventional procedures under systemic heparinization.

Authors:  H-F Wong; C-W Lee; Y-L Chen; Y-M Wu; H-H Weng; Y-H Wang; H-M Liu
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-02       Impact factor: 3.825

4.  Central Pseudo-Aneurysm Formation Following Arterial Closure with a StarClose SE Device: When a StarClose Doesn't Completely Close.

Authors:  Sehrish Memon; Timothy C Ball
Journal:  Am J Case Rep       Date:  2016-03-30

5.  Flip-over of blood vessel intima caused by vascular closure device: A case report.

Authors:  Li-Xia Sun; Xue-Song Yang; Da-Wei Zhang; Bo Zhao; Lian-Lian Li; Qi Zhang; Qing-Zhi Hao
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.